SpringWorks Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	176.67	68.07	104.53	147.65	328.19	46.19
Short-Term Investments	303.15	524.72	269.54	361.4	0	0
Cash & Cash Equivalents	479.82	592.79	374.07	509.05	328.19	46.19
Cash Growth	-19.06%	58.47%	-26.52%	55.11%	610.56%	-
Receivables	5.93	0	0	0	0	0
Inventory	3.1	0	0	0	0	0
Other Current Assets	12.06	6.97	8.84	4.35	3.17	0.84
Total Current Assets	500.91	599.76	382.91	513.4	331.36	47.03
Property, Plant & Equipment	24.09	18.27	4.2	3.02	0.8	0.32
Long-Term Investments	185.34	8.99	62.11	57.21	0.98	0
Other Long-Term Assets	15.45	3.23	3.27	2.57	1.7	1.04
Total Long-Term Assets	224.88	30.48	69.58	62.79	3.47	1.36
Total Assets	725.79	630.24	452.49	576.19	334.83	48.39
Accounts Payable	7.4	8.01	3.43	1.35	2.65	0.77
Deferred Revenue	19.55	19.55	0	0	0	0
Current Debt	1.06	0.48	1.16	1.38	0	0
Other Current Liabilities	50.17	23.01	25.38	14.89	9.32	2.9
Total Current Liabilities	78.17	51.05	29.97	17.61	11.97	3.68
Long-Term Debt	6	4.77	0.13	1.36	0	0
Other Long-Term Liabilities	15.4	16.23	0	0.16	0.79	1.15
Total Long-Term Liabilities	21.4	21	0.13	1.52	0.79	1.15
Total Liabilities	99.57	72.05	30.1	19.13	12.76	4.83
Total Debt	7.06	5.25	1.29	2.73	0	0
Debt Growth	34.39%	306.74%	-52.78%	-	-	-
Retained Earnings	-895.03	-569.93	-292.51	-118.6	-73.03	-22.45
Comprehensive Income	1.19	-0.77	-0.31	0.04	0	0
Shareholders' Equity	626.22	558.19	422.4	557.06	322.07	-19.37
Net Cash / Debt	472.76	587.54	372.78	506.32	328.19	46.19
Net Cash / Debt Growth	-19.54%	57.61%	-26.37%	54.27%	610.56%	-
Net Cash Per Share	7.49	11.03	7.69	11.69	24.72	135.44
Working Capital	422.74	548.71	352.94	495.79	319.39	43.35
Book Value Per Share	9.92	10.47	8.71	12.87	24.26	-56.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).